

NVAC Vaccine Finance Working Group Update

October 23, 2007

Gus Birkhead, MD, MPH

**New York State Department of Health
Chair, NVAC Vaccine Working Group**

NVAC Vaccine Finance Working Group Studies Through CDC

1. Assessment of private provider attitudes regarding vaccine financing

- **Purpose:** To determine the attitudes of private immunization providers regarding the purchase of newly recommended vaccines and reimbursement for vaccine purchase and administration.
- **Methods:**
 - *Design:* Cross-sectional mailed survey
 - *Sample:* National random sample of pediatricians and family physicians, drawn from the AMA Masterfile
- **Results:** Fall 2007

Preliminary Results: Provider Attitudes on Vaccine Financing

- DRAFT – DRAFT – DRAFT
- 64% response rate
- Majority disagreed that reimbursement for vaccine and administration are adequate.
- Almost ½ delayed purchase of vaccine in the last 3 years due only to financial issues.
- 11% seriously considered stopping all vaccination services to privately insured patients in the past year

NVAC Vaccine Finance Working Group Studies Through CDC

2. Assessment of the charges and reimbursements for vaccines and administration fees in private practices

- **Purpose:** Determine the range of prices paid for childhood/adolescent vaccines and administration fees charged, and reimbursement paid for each by their 3 largest insurers.
- **Methods:**
 - Telephone survey of practice managers
 - 30 practices each from 5 non-universal purchase states (5 small, 5 medium, and 5 large from metropolitan and non-metropolitan areas of each state)
 - 20 practices from 2 universal purchase states (10 practices will be selected from 3 areas of each state)
- **Results: Fall 07**

Preliminary Results: Charges and Reimbursements

- DRAFT - DRAFT - DRAFT
- 50-60% response rate
- Wide range in costs, reimbursements and net to practice:

	Cost/Dose			Reimbursement/Dose			Net to Practice/Dose		
	Mean	Max	Min	Mean	Max	Min	Mean	Max	Min
Menactra®	\$86	\$99	\$79	\$95	\$132	\$46	\$9	\$42	\$-41
Gardasil®	\$120	\$130	\$116	\$137	\$188	\$68	\$17	\$60	\$-52

Preliminary Findings

- Wide range in prices and reimbursement
- Multifactorial
- Large scale drop out of providers unlikely
- Clearly possible to make money on vaccinations

Further data collection and analysis underway

NVAC Vaccine Finance Working Group Timeline

- December 2007 – complete next draft of White Paper
- January 8,9 2008 – Stakeholders meeting to get input on draft White Paper
- February NVAC meeting – Present White Paper to full NVAC for endorsement.